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Well-designed head-to-head clinical trials of aspirin and statins are required to document the superiority of either of these agents in the primary prevention of CVDs. Until results of such trials become available, it will be inappropriate either to replace aspirin with statin or to increase the dose of aspirin in the primary prevention of CVDs. Until then, low-dose aspirin (80 mg) should continue to enjoy its long-term monopoly as the drug of mainstay in the primary prevention of CVD; nevertheless, careful patient selection should be made based on age, gender and CV risk.
Being the leading cause of morbidity and mortality, cardiovascular diseases (CVDs) have become a major public health concern globally. Over the past two decades, lifestyle modification (low-fat diet, smoking cessation, increased physical activity, weight management) together with aspirin have been the cornerstone for both primary and secondary prevention for CVDs. However, new clinical trials and meta-analyses have called into question the effectiveness of aspirin in primary prevention [1] , even among patients with diabetes [2, 3] , a disease condition considered as coronary heart disease equivalent. Interestingly, a longitudinal observational study reported an increased CVD risk associated with lowdose aspirin for primary prevention among Chinese patients with type 2 diabetes [4] . The authors further reported a hazard ratio of 2.2 (95% CI = 1.53-3.15, p ! 0.001) for gastrointestinal bleeding and of 1.71 (95% CI = 1.00-2.95, p = 0.051) for hemorrhagic stroke associated with the use of aspirin [4] . On the other hand, recent meta-analyses have strengthened the evidence on the effectiveness of HMG-CoA reductase inhibitors (statins) in primary prevention [5, 6] . A significant risk reduction of 12% in all-cause mortality, 30% in major coronary events and 19% in major cerebrovascular events was reported to be associated with the use of statins [5] . Furthermore, the use of statins was not associated with an increased risk of cancer [5] . However, another meta-analysis reported a 9% increase in risk of incident diabetes (odds ratio = 1.09; 95% CI = 1.02-1.17) associated with the use of statins, with the highest risk among elderly patients [7] . The authors considered the risk of development of diabetes to be low in absolute terms and when compared with reduction in coronary events in patients with moderate to high cardiovascular risk or existing cardiovascular disease, but statins should be used with caution in patients with low cardiovascular risk [7] . Although substantial data are available to support the use of statins in primary prevention, cost-effectiveness is yet to be demonstrated.
It has been argued that perhaps the currently recommended low dose of aspirin is responsible for its lack of effectiveness and a dose increase to 160 mg is advocated [8] . However, increased risk
